Glutamate-based antidepressants: Preclinical psychopharmacology

Biological Psychiatry

Volumn 73, Issue 12, 2013, Pages 1125-1132

  Pilc, Andrzej ^a   Wierońska, Joanna M ^a   Skolnick, Phil ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

AMPA; depression; GLT 1; mGlu2 3; mGlu5; mGlu7; NMDA; xc

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; ANTIDEPRESSANT AGENT; AZD 6765; CP 101 606; DIZOCILPINE; EXCITATORY AMINO ACID TRANSPORTER; GLIAL GLUTAMATE TRANSPORTER 1; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLYX 13; KETAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 7; MK 0657; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRAXOPRODIL; UNCLASSIFIED DRUG;

DEPRESSION; HUMAN; NERVOUS SYSTEM PARAMETERS; NONHUMAN; POSTSYNAPTIC DENSITY; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SYNAPATIC CLEFT; SYNAPSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; PSYCHOPHARMACOLOGY;

EID: 84878396787     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.01.021     Document Type: Review

References (100)

1. R. Trullas, and P. Skolnick Functional antagonists at the NMDA receptor complex exhibit antidepressant actions Eur J Pharmacol 185 1990 1 10
2. S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants Neuropharmacology 66 2013 40 52
3. R. Machado-Vieira, L. Ibrahim, I.D. Henter, and J. Zarate Novel glutamatergic agents for major depressive disorder and bipolar disorder Pharmacol Biochem Behav 100 2012 678 687
4. K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder Brain Res Rev 61 2009 105 123
5. G. Sanacora, G. Treccani, and M. Popoli Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders Neuropharmacology 62 2012 63 77
6. B. Szewczyk, A. Palucha-Poniewiera, E. Poleszak, A. Pilc, and G. Nowak Investigational NMDA receptor modulators for depression Expert Opin Investig Drugs 21 2012 91 102
7. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
8. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J Clin Psychopharmacol 28 2008 631 637
9. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol Sci 30 2009 563 569
10. R. Machado-Vieira, G. Salvadore, L.A. Ibrahim, N. Diaz-Granados, and C.A. Zarate Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders Curr Pharm Des 15 2009 1595 1611
11. H.V. Wheal, Y. Chen, J. Mitchell, M. Schachner, W. Maerz, and H. Wieland Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity Prog Neurobiol 55 1998 611 640
12. M.B. Kennedy Signal-processing machines at the postsynaptic density Science 290 2000 750 754
13. J. Maj, Z. Rogoz, G. Skuza, and H. Sowinska The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test Pol J Pharmacol Pharm 44 1992 337 346
14. E. Przegalinski, E. Tatarczynska, A. Derenwesolek, and E. Chojnackawojcik Antidepressant-like effects of a partial agonist at strychnine- insensitive glycine receptors and a competitive NMDA receptor antagonist Neuropharmacology 36 1997 31 37
15. E. Poleszak, P. Wlaz, A. Wrobel, M. Dybala, M. Sowa, and S. Fidecka Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test Pharmacol Rep 59 2007 595 600
16. R.T. Layer, P. Popik, T. Olds, and P. Skolnick Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715) Pharmacol Biochem Behav 52 1995 621 627
17. N. Li, R.J. Liu, J.M. Dwyer, M. Banasr, B. Lee, and H. Son Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol Psychiatry 69 2011 754 761
18. S. Maeng, C.A. Zarate Jr, J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 2008 349 352
19. T. Kos, and R. Popik A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice Behav Pharmacol 16 2005 155 161
20. C.A. Zarate, J.B. Singh, J.A. Quiroz, G. De Jesus, K.K. Denicoff, and D.A. Luckenbaugh A double-blind, placebo-controlled study of memantine in the treatment of major depression Am J Psychiatry 163 2006 153 155
21. Z. Rogoz, G. Skuza, J. Maj, and W. Danysz Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats Neuropharmacology 42 2002 1024 1030
22. E. Engin, D. Treit, and C.T. Dickson Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models Neuroscience 161 2009 359 369
23. P. Popik, T. Kos, M. Sowa-Kucma, and G. Nowak Lack of persistent effects of ketamine in rodent models of depression Psychopharmacology (Berl) 198 2008 421 430
24. H. Koike, M. Iijima, and S. Chaki Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behav Brain Res 224 2011 107 111
25. J.S.O. Lindholm, H. Autio, L. Vesa, H. Antila, L. Lindemann, and M.C. Hoener The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf(+/-) heterozygous null mice Neuropharmacology 62 2012 391 397
26. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
27. A.J. Bechtholt-Gompf, K.L. Smith, C.S. John, H.H. Kang, W.A. Carlezon, B.M. Cohen, and D. Ongur CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy Psychopharmacology (Berl) 215 2011 689 695
28. C.A. Zarate, N. Brutsche, G. Laje, D.A. Luckenbaugh, S.L.V. Venkata, and A. Ramamoorthy Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression Biol Psychiatry 72 2012 331 338
29. B. Szewczyk, A. Palucha-Poniewiera, E. Poleszak, A. Pilc, and G. Nowak Authors' response: The differences in AMPA receptor dependence on antidepressant-like activity Expert Opin Investig Drugs 21 2012 584 585
30. M. Papp, and E. Moryl New evidence for the antidepressant activity of MK-801, a non- competitive antagonist of NMDA receptors Pol J Pharmacol 45 1993 549 553
31. M. Papp, and E. Moryl Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression Eur J Pharmacol 263 1994 1 7
32. A.M. Redmond, A. Harkin, J.P. Kelly, and B.E. Leonard Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity Eur Neuropsychopharmacol 9 1999 165 170
33. P. Willner Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation Psychopharmacology (Berl) 134 1997 319 329
34. L.S.B. Garcia, C.M. Comim, S.S. Valvassori, G.Z. Reus, L. Stertz, and F. Kapczinski Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats Prog Neuropsychopharmacol Biol Psychiatry 33 2009 450 455
35. P. Skolnick, R.T. Layer, P. Popik, G. Nowak, I.A. Paul, and R. Trullas Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression Pharmacopsychiatry 29 1996 23 26
36. P. Skolnick, B. Legutko, X. Li, and F.P. Bymaster Current perspectives on the development of non-biogenic amine-based antidepressants Pharmacol Res 43 2001 411 422
37. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
38. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, and S. Khalife A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 2010 793 802
39. Krystal JH, Sanacora G, Duman RS (in press): Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry.
40. L. Ibrahim, N. Diazgranados, L. Jolkovsky, N. Brutsche, D. Luckenbaugh, and J. Herring A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder J Clin Psychopharmacol 32 2012 551 557
41. M. Siwek, D. Dudek, I.A. Paul, M. Sowa-Kucma, A. Zieba, and P. Popik Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study J Affect Disord 118 2009 187 195
42. G. Nowak, M. Siwek, D. Dudek, A. Zieba, and A. Pilc Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study Pol J Pharmacol 55 2003 1143 1147
43. G.A. Eby, and K.L. Eby Rapid recovery from major depression using magnesium treatment Med Hypotheses 67 2006 362 370
44. Zarate CA Jr, Mathews D, Lobna I, Chaves JF, Marquart C, Ukoh I, et al. (2012): A randomized trial of a low trapping non-selective N-methyl-D-aspartate (NMDA) channel blocker in major depression [published online ahead of print November 30]. Biol Psychiatry.
45. C. Addy, C. Assaid, D. Hreniuk, M. Stroh, Y. Xu, and W.J. Herring Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease J Clin Pharmacol 49 2009 856 864
46. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
47. A. Alt, E.S. Nisenbaum, D. Bleakman, and J.M. Witkin A role for AMPA receptors in mood disorders Biochem Pharmacol 71 2006 1273 1288
48. J.C. Quirk, and E.S. Nisenbaum LY404187: A novel positive allosteric modulator of AMPA receptors CNS Drug Rev 8 2002 255 282
49. X. Li, J.P. Tizzano, K. Griffey, M. Clay, T. Lindstrom, and P. Skolnick Antidepressant-like actions of an AMPA receptor potentiator (LY392098) Neuropharmacology 40 2001 1028 1033
50. S. Farley, K. Apazoglou, J.M. Witkin, B. Giros, and E.T. Tzavara Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm Int J Neuropsychopharmacol 13 2010 1207 1218
51. A. Alt, J.M. Witkin, and D. Bleakman AMPA receptor potentiators as novel antidepressants Curr Pharm Des 11 2005 1511 1527
52. B. Legutko, X. Li, and P. Skolnick Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator Neuropharmacology 40 2001 1019 1027
53. G. Bagetta, M. Iannone, E. Palma, G. Nistico, and J.O. Dolly N-methyl-D-aspartate and non-N-methyly-D-asapartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats Neuroscience 71 1996 613 624
54. X. Li, A.B. Need, M. Baez, and J.M. Witkin Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J Pharmacol Exp Ther 319 2006 254 259
55. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur Neuropsychopharmacol 17 2007 172 179
56. J.C. Tu, B. Xiao, S. Naisbitt, J.P. Yuan, R.S. Petralia, and P. Brakeman Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins Neuron 23 1999 583 592
57. S. Alagarsamy, M.J. Marino, S.T. Rouse, R.W. Gereau, S.F. Heinemann, and P.J. Conn Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems Nat Neurosci 2 1999 234 240
58. A. Palucha, P. Branski, B. Szewczyk, J.M. Wieronska, K. Klak, and A. Pilc Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol Biochem Behav 81 2005 901 906
59. Z.A. Hughes, S.J. Neal, D.L. Smith, S.J. Sukoff Rizzo, C.M. Pulicicchio, and S. Lotarski Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression Neuropharmacology 66 2013 202 214
60. M. Nakamoto, V. Nalavadi, M.P. Epstein, U. Narayanan, G.J. Bassell, and S.T. Warren Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors Proc Natl Acad Sci U S A 104 2007 15537 15542
61. B.R. Harris, M.A. Prendergast, D.A. Gibson, D.T. Rogers, J.A. Blanchard, and R.C. Holley Acamprosate inhibits the binding and neurotoxic effects of Trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors Alcohol Clin Exp Res 26 2002 1779 1793
62. A. Palucha-Poniewiera, and A. Pilc Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test Prog Neuropsychopharmacol Biol Psychiatry 39 2012 102 106
63. M. Lejoyeux, and P. Lehert Alcohol-use disorders and depression: Results from individual patient data meta-analysis of the acamprosate-controlled studies Alcohol Alcohol 46 2011 61 67
64. J.C. Pecknold, D.J. McClure, L. Appeltauer, L. Wrzesinski, and T. Allan Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J Clin Psychopharmacol 2 1982 129 133
65. R.H. Porter, G. Jaeschke, W. Spooren, T.M. Ballard, B. Buttelmann, and S. Kolczewski Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity J Pharmacol Exp Ther 315 2005 711 721
66. Y.D. Lapierre, and L.K. Oyewumi Fenobam: Another anxiolytic? Curr Ther Res 31 1982 95 101
67. D.D. Schoepp Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system J Pharmacol Exp Ther 299 2001 12 20
68. Y. Tamaru, S. Nomura, N. Mizuno, and R. Shigemoto Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites Neuroscience 106 2001 481 503
69. I. Feinberg, I.G. Campbell, D.D. Schoepp, and K. Anderson The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat Pharmacol Biochem Behav 73 2002 467 474
70. F. Matrisciano, A. Caruso, R. Orlando, M. Marchiafava, V. Bruno, and G. Battaglia Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats Neuropharmacology 55 2008 525 531
71. A. Ahnaou, F.M. Dautzenberg, H. Geys, H. Imogai, A. Gibelin, and D. Moechars Modulation of group II metabotropic glutamate receptor (mGlu(2)) elicits common changes in rat and mice sleep-wake architecture Eur J Pharmacol 603 2009 62 72
72. M.J. Fell, J.M. Witkin, J.F. Falcone, J.S. Katner, K.W. Perry, and J. Hart N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)- 1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical changes J Pharmacol Exp Ther 336 2011 165 177
73. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, and N. Kawashima MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
74. T. Yoshimizu, T. Shimazaki, A. Ito, and S. Chaki An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats Psychopharmacology (Berl) 186 2006 587 593
75. A. Palucha-Poniewiera, J.M. Wieronska, P. Branski, K. Stachowicz, S. Chaki, and A. Pilc On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039 Psychopharmacology (Berl) 212 2010 523 535
76. B. Campo, M. Kalinichev, N. Lambeng, M.E. Yacoubi, I. Royer-Urios, and M. Schneider Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression J Neurogenet 25 2011 152 166
77. E.S. Vizi, A. Fekete, R. Karoly, and A. Mike Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment Br J Pharmacol 160 2010 785 809
78. A. Palucha, E. Tatarczynska, P. Branski, B. Szewczyk, J.M. Wieronska, and K. Kłak Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats Neuropharmacology 46 2004 151 159
79. K. Stachowicz, A. Klodzinska, A. Palucha-Poniewiera, S. Schann, P. Neuville, and A. Pilc The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems Neuropharmacology 57 2009 227 234
80. A. Palucha, K. Klak, P. Branski, H. Putten, P. Flor, and A. Pilc Activation of the mGlu7 receptor elicits antidepressant-like effects in mice Psychopharmacology (Berl) 194 2007 555 562
81. A. Palucha-Poniewiera, P. Branski, T. Lenda, and A. Pilc The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent J Pharmacol Exp Ther 334 2010 1066 1074
82. K.A. Pelkey, X. Yuan, G. Lavezzari, K.W. Roche, and C.J. McBain mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082 Neuropharmacology 52 2007 108 117
83. S.J. Sukoff Rizzo, S.K. Leonard, A. Gilbert, P. Dollings, D.L. Smith, and M.Y. Zhang The mGluR7 allosteric modulator AMN082: A monoaminergic agent in disguise? J Pharmacol Exp Ther 338 2011 345 352
84. A. Palucha-Poniewiera, and A. Pilc A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats Behav Brain Res 238 2013 109 112
85. M. Banasr, J.D. Rothstein, K. Tanaka, R.S. Duman, and G. Sanacora Role of glial glutamate transporter GLT1 (EAAT2) in the antidepressant action of riluzole and ceftriaxone Biol Psychiatry 67 2010 236S-236S
86. C.S. John, K.L. Smith, A. Van't Veer, H.S. Gompf, W.A. Carlezon Jr, and B.M. Cohen Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia Neuropsychopharmacology 37 2012 2467 2475
87. B.P. Brennan, J.I. Hudson, J.E. Jensen, J. McCarthy, J.L. Roberts, and A.P. Prescot Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole Neuropsychopharmacology 35 2010 834 846
88. V. Coric, S. Milanovic, S. Wasylink, P. Patel, R. Malison, and J.H. Krystal Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder Psychopharmacology (Berl) 167 2003 219 220
89. K. Takahashi, H. Murasawa, K. Yamaguchi, M. Yamada, A. Nakatani, and M. Yoshida Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression Behav Brain Res 216 2011 46 52
90. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial Int J Neuropsychopharmacol 13 2010 71 82
91. G. Sanacora, S.F. Kendell, Y. Levin, A.A. Simen, L.R. Fenton, V. Coric, and J.H. Krystal Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms Biol Psychiatry 61 2007 822 825
92. C.A. Zarate, J.L. Payne, J. Quiroz, J. Sporn, K.K. Denicoff, and D. Luckenbaugh An open-label trial of riluzole in patients with treatment-resistant major depression Am J Psychiatry 161 2004 171 174
93. J.D. Rothstein, S. Patel, M.R. Regan, C. Haenggeli, Y.H. Huang, and D.E. Bergles Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature 433 2005 73 77
94. Y.S. Mineur, M.R. Picciotto, and G. Sanacora Antidepressant-like effects of ceftriaxone in male C57BL/6J mice Biol Psychiatry 61 2007 250 252
95. D.A. Baker, H. Shen, and P.W. Kalivas Cystine/glutamate exchange serves as the source for extracellular glutamate: Modifications by repeated cocaine administration Amino Acids 23 2002 161 162
96. G.J. Mcbean Cerebral cystine uptake: A tale of two transporters Trends Pharmacol Sci 23 2002 299 302
97. L. Schmaal, D.J. Veltman, A. Nederveen, W. van den Brink, and A.E. Goudriaan N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: A randomized crossover magnetic resonance spectroscopy study Neuropsychopharmacology 37 2012 2143 2152
98. F.F. Ferreira, C. Biojone, S.R.L. Joca, and F.S. Guimaraes Antidepressant-like effects of N-acetyl-L-cysteine in rats Behav Pharmacol 19 2008 747 750
99. V.M. Linck, L. Costa-Campos, L.K. Pilz, C.R.L. Garcia, and E. Elisabetsky AMPA glutamate receptors mediate the antidepressant-like effects of N-acetylcysteine in the mouse tail suspension test Behav Pharmacol 23 2012 171 177
100. M. Berk, D.L. Copolov, O. Dean, K. Lu, S. Jeavons, and I. Schapkaitz N-acetyl cysteine for depressive symptoms in bipolar disorder - A double-blind randomized placebo-controlled trial Biol Psychiatry 64 2008 468 475